BioSpace News Archive

Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases, and certain severe non-malignant blood, immune and metabolic disorders, today reported financial results for the three-month period ended March 31, 2021,

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the second quarter ended April 30, 2021 and provides a business update.

Surgalign Holdings, Inc. announced that the closing of its previously announced registered direct offering for the issuance and sale of an aggregate of 28,985,508 shares of its common stock and warrants to purchase up to an aggregate of 28,985,508 shares of its common stock at a purchase price of $1.725 per share of common stock and related warrant.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that Executive Vice President and Chief Scientific Officer C. Frank Bennett, Ph.D., is a co-recipient of the 23rd Jacob and Louise Gabbay Award in Biotechnology and Medicine for his innovative work on antisense therapy.

Better Therapeutics, Inc. today announced its team is scheduled to participate in two virtual panel discussions at the Cowen 6th Annual FutureHealth Conference on June 17, 2021.

Veracyte, Inc. today announced new data demonstrating the prognostic utility of the company’s Decipher® Prostate genomic classifier among men with non-metastatic castration-resistant prostate cancer (nmCRPC) have been published online in JAMA Oncology.

Asahi Kasei announces the results of joint research with Nara Medical University regarding the efficacy of 226 nm ultraviolet-C (UVC) LEDs in the inactivation of the coronavirus (SARS-CoV-2) that causes COVID-19, and its effects on animal skin cells

PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has filed its definitive proxy statement with the U.S. Securities and Exchange Commission.

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high potency, fully-human polyclonal antibodies at scale, today announced that Eddie J. Sullivan, PhD, co-founder, president, CEO, will serve as an expert panelist during BIO Digital 2021.